Literature DB >> 20939114

mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC.

Koichi Nonaka1, Hikaru Fujioka, Yasushi Takii, Seigo Abiru, Kiyoshi Migita, Masahiro Ito, Takashi Kanematsu, Hiromi Ishibashi.   

Abstract

AIM: To investigate whether microsomal prostaglandin E synthase-1 (mPGES-1) expression in hepatocellular carcinoma (HCC) and in non-cancerous liver affects HCC prognosis after hepatectomy.
METHODS: The relationship between patient clinical profiles, tumor factors, surgical determinants, and mPGES-1 expression and the recurrence-free survival rate were examined in 64 patients who underwent curative hepatectomy between March 2003 and December 2006.
RESULTS: The scores for mPGES-1 expression were higher in well differentiated and moderately differentiated HCC tissues than in poorly differentiated HCC tissues (well differentiated, 5.1 ± 2.7; moderately differentiated, 5.1 ± 1.7; poorly differentiated, 3.0 ± 1.8). In non-cancerous liver tissues, the mPGES-1 levels were higher in injured liver tissues than in normal tissues. Cirrhotic livers had higher mPGES-1 levels than livers with chronic hepatitis (normal livers, 3.3 ± 0.7; chronic hepatitic livers, 5.4 ± 1.9; cirrhotic livers, 6.4 ± 1.6). A univariate analysis revealed that the recurrence-free survival rate was significantly lower in patients with vascular invasion, a higher mPGES-1 level in non-cancerous liver tissue, a larger tumor diameter (≥ 5 cm), and a lower serum albumin level (≤ 3.7 g/dL). The mPGES-1 expression in HCC tissues did not correlate well with postoperative recurrence. A multivariate analysis demonstrated that the presence of vascular invasion and higher mPGES-1 levels were statistically significant independent predictors for early postoperative recurrence of HCC.
CONCLUSION: Increased mPGES-1 expression in non-cancerous liver tissues is closely associated with the early recurrence of HCC after curative resection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20939114      PMCID: PMC2955255          DOI: 10.3748/wjg.v16.i38.4846

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

Review 1.  Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.

Authors:  L J Crofford; P E Lipsky; P Brooks; S B Abramson; L S Simon; L B van de Putte
Journal:  Arthritis Rheum       Date:  2000-01

2.  Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; K Hamamura; Y Imai; H Yoshida; S Shiina; M Omata
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 3.  The role of cyclooxygenases in inflammation, cancer, and development.

Authors:  C S Williams; M Mann; R N DuBois
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

4.  Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.

Authors:  K Yoshimatsu; D Golijanin; P B Paty; R A Soslow; P J Jakobsson; R A DeLellis; K Subbaramaiah; A J Dannenberg
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

5.  Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.

Authors:  Daisuke Kamei; Makoto Murakami; Yoshihito Nakatani; Yukio Ishikawa; Toshiharu Ishii; Ichiro Kudo
Journal:  J Biol Chem       Date:  2003-03-07       Impact factor: 5.157

6.  Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.

Authors:  Seigou Abiru; Kazuhiko Nakao; Tatsuki Ichikawa; Kiyoshi Migita; Masaya Shigeno; Miyuki Sakamoto; Hiroki Ishikawa; Keisuke Hamasaki; Keisuke Nakata; Katsumi Eguchi
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

7.  Randomized comparison of ultrasonic vs clamp transection of the liver.

Authors:  T Takayama; M Makuuchi; K Kubota; Y Harihara; A M Hui; K Sano; M Ijichi; K Hasegawa
Journal:  Arch Surg       Date:  2001-08

8.  Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis.

Authors:  T Tanioka; Y Nakatani; N Semmyo; M Murakami; I Kudo
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

9.  Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma.

Authors:  Y H Chung; J A Kim; B C Song; G C Lee; M S Koh; Y S Lee; S G Lee; D J Suh
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

10.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Authors:  Charles Cha; Yuman Fong; William R Jarnagin; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  3 in total

Review 1.  Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis.

Authors:  Qing Pang; Kai Qu; Jian-Bin Bi; Su-Shun Liu; Jing-Yao Zhang; Si-Dong Song; Ting Lin; Xin-Sen Xu; Yong Wan; Ming-Hui Tai; Hao-Chen Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 2.  Identification and development of mPGES-1 inhibitors: where we are at?

Authors:  Hui-Hua Chang; Emmanuelle J Meuillet
Journal:  Future Med Chem       Date:  2011-11       Impact factor: 3.808

Review 3.  Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma.

Authors:  Chao Chen; Jun Guan; Xinyu Gu; Qingfei Chu; Haihong Zhu
Journal:  Front Cell Dev Biol       Date:  2022-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.